Pfizer, Nvidia Support AI Drug Discovery company

 

 

With a $80 million funding round, AI company CytoReason plans to bring its disease-modeling platform to the United States in order to expedite the process of finding new drugs.

A $80 million investment has been obtained by the Israeli startup CytoReason to expedite the development of its AI-driven platform for drug discovery and disease modeling.

Founded in 2016, the startup’s platform creates computational disease models for predictive therapeutics. Its AI-powered tool is designed to assist researchers looking for potential disease treatments.
Nvidia, Pfizer, OurCrowd and Thermo Fisher Scientific invested in the startup, which plans to use the funds to accelerate its growth.

CytoReason plans to invest in developing its own database of clinical and molecular data as well as expanding the use of its computational models.

Later this year, the business hopes to build an office in Cambridge, Massachusetts.

CEO and co-founder of CytoReason David Harel stated, “CytoReason is grateful for this infusion of new capital from industry technology powerhouses such as Nvidia, Pfizer and Thermo Fisher.

“Everyone knows that data is not enough on its own and that data modeling holds the key to the future of data-driven insights. CytoReason is at the forefront of this revolution in pharmaceutical research and development.

A Tel Aviv-based startup called CytoReason created an AI-powered platform that extracts insights from patient data to assist pharmaceutical researchers in making data-driven choices.

Using its pharmaceutical data, CytoReason’s platform simulates human diseases at the cellular level to observe how potential treatments interact with the human body, enabling drugs to make their way to patients faster.
The startup has been working with Pfizer since 2019. Pfizer has been using CytoReason’s AI technology to aid in drug development programs.

Pfizer and the startup have collaborated since 2019. Pfizer has been supporting drug development initiatives with the use of CytoReason’s AI technology.

In 2022, Pfizer invested $20 million in the firm to gain the right to license CytoReason’s platform and disease models in exchange for a $110 million contract.

Pfizer’s chief scientific officer, Mikael Dolsten, stated, “Our partnership with CytoReason leverages its state-of-the-art immunology multiomics platform to augment Pfizer’s own research and development capabilities and generate invaluable insights into new drug development pathways for patients.” “We’re excited about our continued collaboration and are pleased with the company’s recent growth.”

The startup claims to work with six of the world’s top 10 pharma companies, including Pfizer. These companies utilize its platform to uncover treatments across various therapeutic areas such as inflammation, therapeutics and immunology.
CytoReason leverages Nvidia’s computing and AI platforms to power its work. Kimberly Powell, Nvidia’s general manager for health care, said the startup achieved 10 times the acceleration for inference of its workloads using the company’s tech.

“Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights,” Powell said.